Drug
ABT-126 clinical trials
Also written ABT-126.
- studies test it
- 14
- open now
- 0
- in phase 3
- 0
- first study started
- 2009
How studies write it
Studies that test it under each name
Development codes
- ABT-126
- 14
Studies by the year they started
14 studies that test it; most in 2012 (6)
| Year | Studies |
|---|---|
| 2009 | 5 |
| 2010 | 1 |
| 2011 | 1 |
| 2012 | 6 |
| 2013 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 5
- Phase 2
- 9
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 14 · Other 0
AbbVie (prior sponsor, Abbott) (8) · Abbott (5) · AbbVie (1)
Studies
Open first, then newest update. How each study uses ABT-126 is read from its arms, and is right about nine times in ten.
Testing it · 14
- This is a Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's DiseaseTerminatedPhase 2AbbVie (prior sponsor, Abbott)NCT01676935Written as ABT-126
- Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's DiseaseTerminatedPhase 2AbbVie (prior sponsor, Abbott)NCT01690195Written as ABT-126
- A Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in SchizophreniaCompletedPhase 2AbbVie (prior sponsor, Abbott)NCT01655680Written as ABT-126
- A Phase 2 Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in SchizophreniaCompletedPhase 2AbbVie (prior sponsor, Abbott)NCT01678755Written as ABT-126
- Safety and Efficacy Study for Cognitive Deficits in Adult Subjects With SchizophreniaCompletedPhase 2AbbVie (prior sponsor, Abbott)NCT01095562Written as ABT-126
- Long-term Safety and Efficacy of ABT-126 in Subjects With Schizophrenia: An Extension Study for Subjects Completing Study M10-855 (NCT01655680)TerminatedPhase 2AbbVieNCT01834638Written as ABT-126
- Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's DiseaseCompletedPhase 2AbbVie (prior sponsor, Abbott)NCT01527916Written as ABT-126
- Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase InhibitorsCompletedPhase 2AbbVie (prior sponsor, Abbott)NCT01549834Written as ABT-126
- Efficacy and Safety Study for Subjects With Mild-to-Moderate Alzheimer's DiseaseCompletedPhase 2AbbVie (prior sponsor, Abbott)NCT00948909Written as ABT-126
- A Phase 1 Study of the Safety, Tolerability and Pharmacokinetics of ABT-126 in Subjects With Alzheimer's DiseaseCompletedPhase 1AbbottNCT01482845Written as ABT-126
- Pharmacokinetic Study of ABT-126 in Healthy VolunteersCompletedPhase 1AbbottNCT00959634Written as ABT-126
- Pharmacokinetic and Exploratory Biomarker Study of ABT-126 in Healthy VolunteersCompletedPhase 1AbbottNCT00912431Written as ABT-126
- Pharmacokinetic Study of ABT-126 in Stable Subjects With SchizophreniaCompletedPhase 1AbbottNCT01043458Written as ABT-126
- A Safety and Tolerability Study of ABT-126 in ElderlyCompletedPhase 1AbbottNCT00867399Written as ABT-126